Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Investor Presentation (August 2019)
22 slides from Anixa Biosciences's investor presentation, Aug 21, 2019
Slide 1: Anixa Biosciences
Aanixa BIOSCIENCES August 2019 NASDAQ:ANIX Amit Kumar, Ph.D. Chairmanand CEO ak@anixa.com
Slide 2: Forward-Looking Statements
orward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Corporate Background
Corporate Background General & Financial Strategy — Low Cost Effective Business Model NASDAQ: ANIX ¢ Invent/in-license technology platforms Bay Area, CA Biotech ¢ Develop technology with partners More than 1 year of cash ¢ Leverage existing infrastructure of No debt partner Headcount: 6 Full-time ¢
Slide 4: Leadership Team
Leadership Team Key Members of Management Amit Kumar, PhD, Chairman, CEO and President . fe * Co-Founder, Executive Chairman of Actym Therapeutics CombiMatrix * Member, Board of Directors, American Cancer Society ea ~altect + Former President and CEO CombiMatrix, recently acquired by Invitae Caltech
Slide 5: Three High Value Programs
Three High Value Programs Breast Cancer Vaccine * Immunize against a-Lactalbumin to prevent Triple Negative Breast Cancer (TNBC) and other breast cancers * Worldwide license * Cleveland Clinic collaboration for IND and clinical trial ynamic * $6.2 MM DOD grant will fund pre-clinical work and two Ph
Slide 6: Breast Cancer Vaccine
Breast Cancer Vaccine Inventor and PI: Vincent K. Tuohy, Ph.D. Mort and Iris November Distinguished Chair in Innovative Cancer Research, Cleveland Clinic Retired Tissue Specific Protein * Expressed at periods of life, but no longer expressed as we age ew o-Lactalbumin —>" ee Galactose Glucose a-LACT
Slide 7: Vaccination Prevents Breast Cancer
Vaccination Prevents Breast Cancer SAFE Vaccinated mice did not exhibit autoimmune damage, while single T-cell infiltrates were seen in non-lactating breast tissue (arrows) Aanixa EFFECTIVE MMTV-neu Mice 100 <S 80 * Vaccinated Controls / \ 100% of a-LACTALBUMIN vaccinated mice do not develop breast
Slide 8: Breast Cancer Vaccine Clinical Trial Plan
Breast Cancer Vaccine Clinical Trial Plan Funded by Department of Defense (DOD) Grant $6.2 MM Pre-Clinical Studies GLP Tox Phase 1a Trial IND filin, 5 e + TNBC patients who have Bhave 40 tia) undergone standard of care * Healthy women with BRCA1 mutations * Will monitor pro-inflammatory T-cell respo
Slide 9: Summary: Breast Cancer Vaccine
Summary: Breast Cancer Vaccine * Cleveland Clinic collaboration * DOD funded program; $6.2 Million o Pre-clinical o Two phase 1 clinical trials * Pre-IND meeting with FDA completed * Plan to file IND by end of 2019 * Begin first clinical trial in 2020 Data published: Cancers, 2016, 8, 56. Manixa
Slide 10: CAR-T Technology: Background & Opportunity
CAR-T Technology: Background & Opportunity CAR- Technology has made great inroads in B-Cell cancers * Durable responses (50-80% of patients) * Multibillion dollar valuations and big pharma deals o Novartis - First approved product by FDA o Kymriah for ALL- Acute Lymphoblastic Leukemia e Second appro
Slide 11: Anixa's Unique CER-T Approach for Solid Tumors
Anixa’s Unique CER-T Approach for Solid Tumors Novartis, JUNO, KITE and others Anixa’s CAR-T Program for Ovarian Cancer working on B-Cell cancers FSHR- Follicle Stimulating Hormone Receptor Chimeric Endocrine Receptor T-Cell Cancerous B-cell CD19 protein — (antigen) scFv-antibody fragment engineered
Slide 12: FSHR ONLY Expressed in Ovaries and Testis
FSHR ONLY Expressed in Ovaries and Testis *In Healthy Humans* 5 0.0025) Qn 8 0.002 oa ly in Fetal Th 3 0.0015 ia ill * FSHR expressed on the blood vessels s” \ of many TUMORS ra \ £ 0.001- a 4 XQ ¢ This therapy will be anti-angiogenic ® 0.0005- NG for many types of cancer, enabling a Q 0 “ ¥ i portf
Slide 13: Pre-Clinical Data
Pre-Clinical Data FSH-Targeted chimeric receptors re-direct primary human T cells against FSHR+ ovarian cancer cells 707 -=-FSHCER 60-4 -& Mock 4 50: 40 30. 20 10: () 41 1:5 1:10 Target:Effector ratio Ovarian Cancer —> Breast Cancer ‘Source: Perales-Puchalt et al. “Follicle-stimulating hormone recep
Slide 14: Our Magic Bullet Reagan
Our Magic Bullet Reagan Tumorsinduce rapid Tumor blood vessel growth to nourish themselves + Many tumors have blood vessels where FSHRis expressed even though healthy tissue does not show such expression © Physiologically, FSHR must be helpful in enabling tumors to create vasculature © Outside of th
Slide 15: Summary: CAR-T Program
Summary: CAR-T Program * Exclusive worldwide license from The Wistar Institute o Tested human CAR-T in immunocompromised mice against human ovarian cancer o Tested murine CAR-T in immunocompetent mice against murine ovarian cancer o Tested human CAR-T in immunocompromised mice against human breast c
Slide 16: Early Cancer Detection — Liquid Biopsy
Early Cancer Detection — Liquid Biops Anixa is developing a blood test for early cancer detection called Cchek™ €chek’ Early Cancer Detection Goal: To determine a patient’s cancer status from a simple blood draw without a biopsy Aanixa
Slide 17: Competing Liquid Biopsy Approaches
Competing Liquid Biopsy Approaches All these approaches require Hi * the tumor to be large enough * Circulating tumor DNA (ctDNA) il oe iene aie, * Circulating tumor Cells (CTCs) Ene|bIbGd Stresnit * Circulating tumor Exosomes . . . All these approaches tend to * Other biomarkers coming directly fro
Slide 18: Artificial Intelligence (AI) Analysis
Artificial Intelligence (Al) Analysis Training Neural Network Normal Patient Samples ——EEE Cancer Patient Samples —— Patient Sample Malignancy or Normal
Slide 19: Early Screening Studies
Early Screening Studies: Multiple Cancer Types Stages 1-4 Total Samples: 248 Training Samples: 150 Blind Samples: 98 Breast Cancer Screening Study: Stages 1-2 only Total Samples: 179 Training Samples: 132 Blind Samples: 47 Prostate Cancer Screening Study: All Gleason Scores Internal Study Total Samp
Slide 20: Cchek Prostate Cancer Confirmation (PCC)
€chek’prostate Cancer Confirmation (PCC * Prostate cancer typically diagnosed by elevated PSA level and prostate examination, followed by biopsy Pred Prostate Cancer Confirm: prostate cancer in a men * 1.5 million prostate biopsies in the US annually ae ¢ Nearly 90% are negative Training Samples: 15
Slide 21: Anixa's Liquid Biopsy
a) ° . ° Anixa’s Liquid Biopsy * We monitor the patient’s white blood cells to detect tumors o We let the the patients body tell tell us there is a tumor o We do NOT measure tumor DNA, circulating tumor cells or tumor exosomes * We combine flow cytometry and artificial intelligence to perform the an
Slide 22: Anixa's Value-Creating Near-Term Milestones
Anixa’s Value-Creating Near-Term Milestones Breast Cancer Vaccine CAR-T Program Filing of IND for clinical trials-Q4 2019 Filing of IND for clinical trial-Q4 2019 Approval of IND by FDA Approval of IND by FDA Patient recruitment Patient recruitment First patient dosed and initiation of clinical tria
Anixa Biosciences — Investor Presentation (August 2019) on 6ix